[ad_1]
Rutgers researchers have created a device to determine if targeted chemotherapy drugs are acting on patients with cancer.
According to a review of the journal, the wearable device, which uses artificial intelligence and biosensors, is 95.9% accurate in counting living cancer cells when they pbad through electrodes. Microsystems and nanotechnologies.
"We have built a portable platform that can predict whether patients will respond positively to targeted cancer therapy," said Mehdi Javanmard, senior author, badistant professor in the department of electrical and computer engineering at the School of Engineering. Rutgers University in New Brunswick. "Our technology combines artificial intelligence and sophisticated biosensors that process small amounts of fluid to determine whether cancer cells are sensitive or resistant to chemotherapy drugs."
The device provides immediate results and will allow more personalized interventions for patients, as well as better management and better detection of the disease. It can quickly badyze cells without having to stain them, allowing for further molecular badysis and instant results. Current devices rely on staining, limiting cell characterization.
"We plan to use this new device as a point-of-care diagnostic tool to evaluate patient response and personalization of therapy," the study said.
Treatment of cancer patients often requires drugs that kill tumor cells, but chemotherapy destroys both tumor cells and healthy cells, causing side effects such as hair loss and gastrointestinal problems.
Co-author, Joseph R. Bertino, a researcher-in-residence at the Rutgers Cancer Institute in New Jersey and a professor at Rutgers School of Medicine Robert Wood Johnson, and his team have previously developed a therapeutic approach targeting cancer cells, such as those of B-cell lymphoma, multiple myeloma and epithelial carcinomas. It binds a chemotherapy drug to an antibody so that only the tumor cells are targeted and minimizes interactions with healthy cells. Patients will respond positively to this therapy if their tumor cells generate a protein called matriptase. Many patients will benefit while the side effects of standard chemotherapy are minimized.
"New technologies such as this one can really have a positive impact on the quality of care and enable health care providers and patients to realize cost savings," Bertino said.
The Rutgers team tested its new device using samples of cancer cells treated with different concentrations of a targeted anti-cancer drug. The device detects whether a cell is alive according to the change in its electrical properties as it pbades through a tiny fluidic hole. The next step is to perform tests on tumor samples from patients. The researchers hope that the device will eventually be used to test cancer treatments on tumor samples of patients prior to the administration of the treatment.
Source of the story:
Material provided by Rutgers University. Note: Content can be changed for style and length.
Source link
